Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Nov
05
Today In Oncology
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Pediatric Brain Tumors Prognostic AI Model Guides Precision Therapy Choices
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo